Table 2.

Cardiac magnetic resonance‐derived cardiac functional parameters and dimensions, pathology's activity, and its localization

	All patients n = 27	CMR‐based diagnosis of cardiac sarcoidosisa n = 14	CMR‐based exclusion of cardiac sarcoidosis n = 13	P‐value
CMR‐assessed cardiac functional parameters and dimensions
LVEF (%)	58.8 ± 10.3	57.0 ± 11.4	60.7 ± 9.0	0.36
LVEDV (mL)	141.8 ± 48.5	150.1 ± 59.2	132.9 ± 33.6	0.37
IVSD (mm)	9.8 ± 1.6	9.5 ± 1.4	10.3 ± 1.7	0.20
CMR‐assessed pathology's activity, n (%)
Only non‐viable tissue damage, as assessed by late gadolinium enhancement		7 (50.0%)
Both acute inflammatory and non‐viable tissue damage, as assessed by early relative gadolinium enhancement, T2 imaging, and late gadolinium enhancement		6 (42.9%)
Only acute inflammatory tissue damage, as assessed by early relative gadolinium enhancement		1 (7.1%)
CMR‐assessed localization of LGE according to AHA's segmentation and nomenclature,19 n (%)
1 basal anterior		3 (8.3%)
2 basal anteroseptal		3 (8.3%)
3 basal inferoseptal		3 (8.3%)
4 basal inferior		2 (5.6%)
5 basal inferolateral		3 (8.3%)
6 basal anterolateral		2 (5.6%)
7 mid‐anterior		4 (11.1%)
8 mid‐anteroseptal		4 (11.1%)
9 mid‐inferoseptal		5 (13.9%)
10 mid‐inferior		0 (0.0%)
11 mid‐inferolateral		2 (5.6%)
12 mid‐anterolateral		4 (11.1%)
13 apical anterior		1 (2.8%)
14 apical septal		0 (0.0%)
15 apical inferior		0 (0.0%)
16 apical lateral		0 (0.0%)
17 apex		0 (0.0%)

Data are presented as mean ± SD or total number and percentage (in parentheses), as appropriate.

AHA, American Heart Association; CMR, cardiovascular magnetic resonance; IVSD, diastolic interventricular septal thickness; LGE, late gadolinium enhancement; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction.

^aDetection of cardiac sarcoidosis relied on presence of LGE; in case of early relative gadolinium enhancement or pathological T2‐weighted imaging, cardiac sarcoid involvement was suspected.